GeoVax Implements Reverse Stock Split to Maintain Nasdaq Listing Amid Clinical Development

GeoVax Labs, Inc. has announced a reverse stock split of its common stock at a 1-for-25 ratio, approved by stockholders on November 26, 2025, to regain compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The split becomes effective on January 9, 2026, with trading on a split-adjusted basis expected to begin at the market open on January 12, 2026. This corporate action reduces the total issued and outstanding shares from 43,303,682 to approximately 1,732,148, though stockholder ownership percentages and voting rights remain largely unchanged, with fractional shares rounded up to whole numbers.

The reverse stock split is crucial for GeoVax to maintain its Nasdaq listing, which provides visibility and access to capital markets essential for funding ongoing clinical trials. The company's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine in three Phase 2 trials, targeting immunocompromised patients, those with chronic lymphocytic leukemia, and healthy individuals previously vaccinated with mRNA vaccines. In oncology, GeoVax is advancing Gedeptin®, an oncolytic solid tumor therapy that recently completed a Phase 1/2 trial for advanced head and neck cancers, with further details available on their website at https://www.geovax.com.

GeoVax is also developing a vaccine for Mpox and smallpox, anticipating progression directly to Phase 3 trials based on recent European Medicines Agency guidance. The company's strong intellectual property portfolio supports these technologies, with worldwide rights to its products. However, forward-looking statements in the release highlight risks, including clinical trial outcomes, regulatory approvals, manufacturing capabilities, and capital requirements, as detailed in periodic reports filed with the SEC. The reverse stock split underscores the financial challenges biotech firms face while advancing innovative therapies, emphasizing the importance of market compliance for sustaining research and development efforts in competitive fields like immunotherapy and vaccine development.